SPARCtool updated to version 8.2

version 8.2 release notes (Sept 2017)

www.sparctool.com 

SPARCtool

• Removed the US-specific edoxaban renal warnings as monographs differ on this worldwide. Replaced it with the same renal function warning as other NOACs, which is consistent with all edoxaban monographs.
• Added “Text for EMR” box for be cut-and-paste into EMR. Thank you, Mark McConnell, for this suggestion.

SPARCmobile

• Removed the US-specific edoxaban renal warnings as monographs differ on this worldwide. Replaced it with the same renal function warning as other NOACs, which is consistent with all edoxaban monographs.
• added an estimate for “Patient’s annual risk of stroke or TIA with no therapy if they did NOT have AF (for comparison):” based on Mitchell LB, Southern DA, Galbraith D, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100(19):1524–1530. doi:10.1136/heartjnl–2013–305303. CHA2DS2-VASc preducts stroke in non-AF patients simiarly well to AF patients. The risk estimates are much lower for non-AF patients, of course. This is added to SPARCtool based on feedback that it is valuable for patients to see how much higher their stroke risk is because of AF vs. without it.

Bleeding - The Long & Short of It - Best Science Medicine Course 2017

Handout

Know Your Birth Control Rights

Updated! 

SPARCtool Updated

version 6.21 release notes

SPARCmobile

• updated the disclaimer
• fixed truncated renal dysfunction warning for new OACs on iPhone and increased visibility of warnings.
• changed text of the warnings to “RENAL FUNCTION WARNING: Consult product monograph.” - dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
• lightened most of the fill colors
• updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
• corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
• added tabular view of the risks

SPARCtool

• updated the disclaimer
• changed text of the warnings to "WARNING: may be contraindicated or require dosage reduction depending on degree of renal dysfunction. Consult your country's monograph."
• dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
• lightened most of the fill colors
• updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
• corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
• added tabular view of the risks
• added graphical representation of the risks (requires Adobe Flash to view)

SPARCtool Updated to version 6.1

Release Notes

version 6.1 release notes

• edited mobile/standard links to map to new site www.sparctool.com
• edited sparcnotes links to map to new site and completely rewrote and reorganized SPARCtool Notes
• fixed date field width on regular version
• updated CHADS2 and CHA2DS2-VASc risk estimates to use BMJ 2011;342:d124, 10 year followup estimates.
• upated all the CHADS2 risk descriptors to match the CHADS-VASc one based on BMJ 2011;342:d124, which is paraphrased as "ischemic stroke+thromboembolism"
• updated warfarin population average major bleeding risk from 2.6 to 3.8%/year based on CMAJ November 26, 2012 cmaj.121218
• add a reference for bleeding risk CPR vs. clinician judgement
• added a warning for dabigatran, rivaroxaban, apixaban if "abnormal renal function" is checked in HAS-BLED
• added a disclaimer to top of both tools